Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Atea Pharmaceuticals Inc (AVIR)

125 + Investors. Track Smart Money conviction in AVIR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +15
Streak
1Q ▲
Buyers last Q
57%

Smart Money Signals — AVIR

Based on 126 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added AVIR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (98% of max)

98% of all-time peak
126 hedge funds hold AVIR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +20% more funds vs a year ago

fund count last 6Q
+21 new funds entered over the past year (+20% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 57% buying

65 buying49 selling
Last quarter: 65 funds bought or added vs 49 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+14 vs last Q)

new funds entering per quarter
Funds opening a new AVIR position: 12 → 12 → 12 → 26. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

57% of holders stayed for 2+ years

■ 57% conviction (2yr+) ■ 21% medium ■ 21% new
72 out of 126 hedge funds have held AVIR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +54% but shares only +6% — price-driven

Value
+54%
Shares
+5%
Last quarter: the total dollar value of institutional holdings rose +54%, but actual share count only changed +6%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

11 → 12 → 12 → 12 → 26 new funds/Q
New funds entering each quarter: 12 → 12 → 12 → 26. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 66% veterans vs 21% newcomers

■ 66% veterans ■ 12% 1-2yr ■ 21% new
Entry-cohort mix of 128 holders: 85 (66%) are 2+ year veterans, 16 entered 1–2 years ago, and 27 (21%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 53% AUM from top-100 funds

53% from top-100 AUM funds
40 of 126 holders are among the 100 largest funds by AUM, controlling 53% of total institutional value in AVIR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
3.6
out of 10
Low Exit Risk
Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — AVIR

In 2026 Q1, 65 hedge funds were net buyers of AVIR (26 opened a new position, 39 added to an existing one), while 49 reduced or exited (38 trimmed, 11 sold completely) — a 57% buyer ratio, indicating a slight buying edge. 53% of total institutional value in AVIR is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +15 funds (more new holders than closures). Total institutional holders: 126.

Hedge Fund Ownership: AVIR

How many hedge funds hold AVIR — quarterly history vs. share price
Quarterly hedge fund ownership of AVIR vs. share price

Market Analysis: AVIR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: AVIR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Atea Pharmaceuticals Inc (AVIR) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much AVIR has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
AVIR
+10.1%
XLV
+5.5%

AVIR outperformed XLV by +4.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
AVIR
+0.0%
XLV
+0.0%

Since the filing became public, AVIR outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

15 top-rated funds 3 high-conviction
Consensus
5.2
/ 10
breadth
×
Elite
3.9
/ 10
conviction
Hedge Fund Positioning: AVIR
2026 Q2 Stats Unlock in 4 days 125 + Investors

Track Smart Money conviction in AVIR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 125 111 12.61%
13F Shares 60M 57M 5.77%
Total Value $313M $203M 54.05%
New Positions 25 12 +13
Increased Positions 39 29 +10
Closed Positions 11 13 -2
Reduced Positions 37 44 -7
Total Calls 2 0 100%
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: AVIR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

125 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in AVIR. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 AVIR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 BML Capital Management, LLC 18.36% 6,952,330 $32.3M
2 Rosalind Advisors, Inc. 1.85% 1,070,550 $5.0M
3 CM Management, LLC 1.05% 355,000 $1.7M
4 Tang Capital Management LLC 1.02% 4,814,700 $22.4M
5 Bain Capital Life Sciences Investors, LLC 0.57% 2,075,639 $9.7M
6 Aldebaran Capital, LLC 0.31% 88,180 $410K
7 Auour Investments LLC 0.24% 177,000 $823K
8 Rangeley Capital, LLC 0.18% 43,500 $202K
9 Spark Investment Management LLC 0.15% 16,200 $75K
10 Nano Cap New Millennium Growth Fund L P 0.13% 35,000 $163K
11 Opaleye Management Inc. 0.10% 235,000 $1.1M
12 Sunpointe, LLC 0.02% 11,943 $56K
13 Bridgeway Capital Management, LLC 0.01% 130,900 $609K
14 Banque Pictet & Cie SA 0.01% 345,077 $1.6M
15 Certified Advisory Corp 0.01% 24,500 $114K
16 Headlands Technologies LLC 0.01% 16,619 $77K
17 Renaissance Technologies LLC 0.01% 1,131,200 $5.3M
18 RBF Capital, LLC 0.01% 30,000 $140K
19 Two Sigma Investments, LP 0.01% 1,506,697 $7.0M
20 Susquehanna Portfolio Strategies, LLC 0.00% 62,073 $289K
21 China Universal Asset Management Co., Ltd. 0.00% 12,736 $59K
22 Fmr LLC 0.00% 12,004,064 $55.8M
23 Algert Global LLC 0.00% 38,520 $179K
24 Strs Ohio 0.00% 117,700 $547K
25 Versant Capital Management, Inc 0.00% 4,220 $20K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Atea Pharmaceuticals Inc (AVIR)

What does the Smart Money Trend signal show for AVIR?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added AVIR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for AVIR?

Slight buying edge — 57% buying: Last quarter: 65 funds bought or added vs 49 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for AVIR holders?

Elite ownership — 53% AUM from top-100 funds: 40 of 126 holders are among the 100 largest funds by AUM, controlling 53% of total institutional value in AVIR. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held AVIR?

57% of holders stayed for 2+ years: 72 out of 126 hedge funds have held AVIR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Atea Pharmaceuticals Inc (AVIR) following the 2026 Q2 hedge fund 13F filings?

As of today, AVIR has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), AVIR has gained +10.1% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →